Skip to main content
construction release_alert
Profile editing will be unavailable for Scholars@Duke profiles from June 11-24, 2026 as manual profile data entry transitions to Elements. More information about the transition.
cancel

Kimberly Lynn Blackwell

Adjunct Professor in the Department of Medicine
Medicine, Medical Oncology
Duke Box 3893, Durham, NC 27710
Room 3818 Duke South, Durham, NC

Overview


Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Current Appointments & Affiliations


Adjunct Professor in the Department of Medicine · 2018 - Present Medicine, Medical Oncology, Medicine

In the News


Published February 12, 2016
Editorial: At Duke, Biden launches a ‘moonshot’ to beat cancer
Published February 1, 2016
A diet high in fiber may help protect against breast cancer
Published September 29, 2015
U.S. Archivist David Ferriero to Address Annual Founders’ Day Ceremony

View All News

Recent Publications


The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Journal Article J Clin Oncol · May 10, 2026 PURPOSE: Patients with stage II/III human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes ... Full text Link to item Cite

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

Journal Article Npj Precision Oncology · December 1, 2025 Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating ... Full text Cite

Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.

Journal Article Mol Diagn Ther · July 2023 INTRODUCTION: Cancers assume a variety of distinct histologies, and may originate from a myriad of sites including solid organs, hematopoietic cells, and connective tissue. Clinical decision-making based on consensus guidelines such as the National Compreh ... Full text Link to item Cite
View All Publications

Recent Grants


Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer

ResearchCo Investigator · Awarded by Department of Defense · 2016 - 2024

Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy

ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2022

Single cell functional dissection of tumor microenviornment-driven drug resistance

ResearchCollaborator · Awarded by National Institutes of Health · 2018 - 2020

View All Grants

Education


Mayo School of Health Sciences · 1994 M.D.